Search Videos by Topic or Participant
Browse by Series:

Discussing Genetic Testing in Colorectal Cancer

Insights From:Tanios Bekaii-Saab, MD, Ohio State University-James Cancer Hospital; Cathy Eng, MD, FACP, MD Anderson Cancer Center; John L. Marshall, MD, Georgetown University Medical Center
Published: Tuesday, Aug 04, 2015

 
Understanding the genetics of colorectal cancer can help determine an optimal treatment strategy, making it important to have a detailed discussion with patients regarding the value of genetic testing, states Tanios Bekaii-Saab, MD. The concept of genetic testing should be introduced during initial treatment discussions or as a follow-up discussion, Bekaii-Saab advises.
 
Proper communications regarding mutations as drivers of cancer growth is important, says Saab. There may be available treatments that can target these drivers and inhibit the growth and spread of disease. It is also important to distinguish between the genetics of the tumor and the patient’s own genetics.

Terminology, such as RAS mutations and microsatellite instability, can complicate discussions with patients, says John L. Marshall, MD. In order to clearly present complex information to patients, it is important for clinicians themselves to be informed regarding all aspects of the disease and its management, adds Marshall.
 
Slider Left
Slider Right

 
Understanding the genetics of colorectal cancer can help determine an optimal treatment strategy, making it important to have a detailed discussion with patients regarding the value of genetic testing, states Tanios Bekaii-Saab, MD. The concept of genetic testing should be introduced during initial treatment discussions or as a follow-up discussion, Bekaii-Saab advises.
 
Proper communications regarding mutations as drivers of cancer growth is important, says Saab. There may be available treatments that can target these drivers and inhibit the growth and spread of disease. It is also important to distinguish between the genetics of the tumor and the patient’s own genetics.

Terminology, such as RAS mutations and microsatellite instability, can complicate discussions with patients, says John L. Marshall, MD. In order to clearly present complex information to patients, it is important for clinicians themselves to be informed regarding all aspects of the disease and its management, adds Marshall.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x